source
- Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 successSilence Therapeutics announced that its siRNA candidate divesiran achieved its primary endpoint in a Phase 2 study in patients with polycythemia vera, a rare blood cancer. The trial results showed…
- BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme assetBioMarin announced it will stop development of BMN 401, an enzyme replacement therapy acquired in its $270 million purchase of Inozyme Pharma. The decision follows the Phase 3 ENERGY trial in pati…